149 related articles for article (PubMed ID: 37830379)
1. Elephantiasis verrucous lesions on psoriatic plaque improved with anti-IL-23p19 antibody therapy.
Sugioka K; Kondo M; Yamanaka K
J Dermatol; 2024 Mar; 51(3):e77-e78. PubMed ID: 37830379
[No Abstract] [Full Text] [Related]
2. Systemic photochemotherapy decreases the expression of IFN-γ, IL-12p40 and IL-23p19 in psoriatic plaques.
Ravić-Nikolić A; Radosavljević G; Jovanović I; Zdravković N; Mitrović S; Pavlović S; Arsenijević N
Eur J Dermatol; 2011; 21(1):53-7. PubMed ID: 21227895
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
[TBL] [Abstract][Full Text] [Related]
4. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
[TBL] [Abstract][Full Text] [Related]
5. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
Xu S; Zhang X; Pan M; Shuai Z; Xu S; Pan F
Int Immunopharmacol; 2019 Oct; 75():105841. PubMed ID: 31465912
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review.
Salimi S; Yamauchi PS; Thakur R; Weinberg JM; Kircik L; Abdelmaksoud A; Wollina U; Lotti T; Sharma A; Grabbe S; Goldust M
Dermatol Ther; 2020 Jul; 33(4):e13800. PubMed ID: 32530083
[TBL] [Abstract][Full Text] [Related]
7. Tildrakizumab for the treatment of psoriasis.
Bangert C; Kopp T
Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
[TBL] [Abstract][Full Text] [Related]
8. A case of elephantiasis nostras verrucosa treated by acitretin.
Polat M; Sereflican B
J Drugs Dermatol; 2012 Mar; 11(3):402-5. PubMed ID: 22395594
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
McDonald J; Maliyar K; Gooderham MJ
Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
[TBL] [Abstract][Full Text] [Related]
10. Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
Paton DM
Drugs Today (Barc); 2019 Oct; 55(10):605-613. PubMed ID: 31720558
[TBL] [Abstract][Full Text] [Related]
11. Acute generalized pustular psoriasis successfully treated with the IL-23p19 antibody risankizumab.
Heyer S; Seiringer P; Eyerich S; Pilz AC; Steimle-Grauer SA; Eyerich K; Biedermann T; Böhner A
J Dtsch Dermatol Ges; 2022 Oct; 20(10):1362-1364. PubMed ID: 36067528
[No Abstract] [Full Text] [Related]
12. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
[TBL] [Abstract][Full Text] [Related]
13. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
Li L; Wu Z; Wu M; Qiu X; Wu Y; Kuang Z; Wang L; Sun T; Liu Y; Yi S; Jing H; Zhou S; Chen B; Wu D; Wu W; Liu J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107008. PubMed ID: 33069927
[TBL] [Abstract][Full Text] [Related]
14. [Verrucous elephantiasis: a maximum variant of lymphedema].
Schmeller W; Hoos A
Hautarzt; 1989 May; 40(5):276-80. PubMed ID: 2737903
[TBL] [Abstract][Full Text] [Related]
15. Tildrakizumab for Moderate-to-Severe Plaque Psoriasis.
Mui UN; Patel RR; Vangipuram R; Tyring SK
Skin Therapy Lett; 2019 Nov; 24(6):1-4. PubMed ID: 31801012
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis.
Yawalkar N; Tscharner GG; Hunger RE; Hassan AS
J Dermatol Sci; 2009 May; 54(2):99-105. PubMed ID: 19264456
[TBL] [Abstract][Full Text] [Related]
17. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
[TBL] [Abstract][Full Text] [Related]
18. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
Toichi E; Torres G; McCormick TS; Chang T; Mascelli MA; Kauffman CL; Aria N; Gottlieb AB; Everitt DE; Frederick B; Pendley CE; Cooper KD
J Immunol; 2006 Oct; 177(7):4917-26. PubMed ID: 16982934
[TBL] [Abstract][Full Text] [Related]
19. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
20. Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L; Maloney V; Gordon KB
Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
